Conference abstract · 16 Sep 2020
Review articlePublished 1 Oct 2019
Biosimilar Drug Development and Approval Process
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The U.S. Food and Drug Administration (FDA) is responsible for advancing the public health by helping to review and evaluate biosimilar innovations that make medicines safer and more effective and by helping the public get the accurate, science-based information it needs to use medicines to maintain and improve public health. This presentation emphasizes quality system approaches to the development and availability of new drug information presented in the premarket applications. For approvals of biosimilars, the sponsors of premarket applications must present analytical characterization, pharmacokinetic (PK) and pharmacodynamic (PD) profiles, and comparative clinical studies to demonstrate that a proposed biosimilar is highly similar to a licensed reference product. It is recommended that a proposed bio similar product be tested for intended clinical use described in the licensed reference product’s labeling. The protocol requires a sponsor to describe the bio similar product’s PK/PD clinical data comparing its safety, efficacy, and immunogenicity to that of the reference product. FDA reviews clinical safety and efficacy of the biosimilar product and it is essential that any residual risks and hazards are mitigated to acceptable levels. FDA emphasizes the quality system approach to design and development studies by ensuring that organized data and appropriate labeling are presented in support of the new biosimilar’s intended clinical use. Emphasis is placed on quality-by-design (QbD) approach to design of studies by providing guidances for analysis and expected clinical PK/PD data for the use of biosimilars in appropriate patient population studies. FDA field investigators evaluate the biosimilar product’s c-GMP risk-based requirements and make recommendations based on whether the manufacturer has the required checks and balances in place and whether the manufacturer verifies and validates the implementation of critical quality attributes (CQAs) of the proposed biosimilar product. Biosimilar applications are approved based on totality of evidence described in U.S. FDA guidance documents.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Article · 30 Sep 2024
Clinical Trials and Regulatory Approvals: Navigating the Drug Development Process
Research article · 24 Jun 2015
From Idea to Market: The Drug Design, Development & Approval Process
Conference abstract · 26 Oct 2015
CMC Consideration for Biosimilar Drug Development and Manufacturing Process
Perspective · 28 Dec 2024
Drug Regulation and Approval: Impact of Accelerated Processes in the COVID Era
More from this journal
The newest in Journal of Pharmaceutical Sciences & Emerging Drugs.
Research article · 18 Feb 2025
Comparative Biowaiver Study of Moxifloxacin in Immediate Release of Oral Solid Dosage Form
Perspective · 23 Aug 2024
Drug Intoxication in Adolescents: Warning Signs and Prevention
Short communication · 20 Aug 2024
Bio-organic Chemistry Approaches to Modulating Protein- Ligand Interactions
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutical Sciences & Emerging Drugs
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Kaiser J Aziz”

